During this special interest group meeting, you’ll learn from speakers well-versed in breast cancer therapies, testing, and patient care. Speakers will teach you key patient education messages for HER-2/neu agents, describing their pharmacologic differences, administration schedule, and toxicity profile. You’ll then learn to teach patients about the differences between genetic and genomic testing, as well as the strengths and limitations of several genomic assays. You’ll also learn how to implement a successful art program for patients with breast cancer.

**Content Area:** Clinical Practice

**Content Level:** Intermediate

**Coordinator:**
Debbie Tuttle, FNP-BC, AOCNS, CBCN
Oncology Nurse Practitioner
California Oncology
Visalia, CA
djtuttle2011@att.net

**Full Disclosure:**
Nothing to Disclose

**Speaker:**
Jenelle Higton, .
Executive Director
The Art of Life Cancer Foundation
Fresno, CA
jenelle.artoflife@gmail.com

**Full Disclosure:**
California Oncology of the Central Valley. Administrator

**Speaker:**
Renita Vance, MSN, RN
Senior Oncology Clinical Coordinator
Genentech BioOncology
Everett, WA
rvance@gene.com

**Full Disclosure:**
Genentech BioOncology. Employee

**Objectives:**
At the end of this session, participants will be able to:
1. Learn how to educate your patients on HER2/neu agents.
2. Describe the benefits and elements of a formalized art program for patients with breast cancer and their caregivers.
3. Learn how to articulate genomic testing to patients with breast cancer.

**Content Outline:**
I. How to educate your patients on “Him and Her2 Neu" agents
   A. Compare the pharmacologic differences and uses of the currently approved Her2 Neu agents.
   B. Describe the specific schedule of administration and toxicity profile of each agent and when administered as dual agent.
   C. Define the key patient education messages for breast cancer patients who will receive these agents along with self-care and monitoring guidelines.

II. The “Art of Life” for patients with breast cancer
   A. Define the benefits of a formalized art program for breast cancer patients and their families and caregivers.
   B. Recognize the elements and resources required to implement an art program for breast cancer survivors in a community setting.

III. How to articulate genomic testing for your patients with breast cancer
   A. Describe the purpose and appropriate use of genomic assays for newly diagnosed breast cancer patients.
   B. Recognize the strengths and limitations of several genomic assays.
   C. Identify the best way to articulate genomic testing to patients so they do not confuse genomic and genetic testing.